Department of Lymphoma and Hematology, Hunan Cancer Hospital Report issue

Academic/Hospital Phase 2

Organization Overview

First Clinical Trial
2020
NCT04414969
First Marketed Drug
None
First NDA Approval
None
Last Known Activity
2020

Timeline

NOW
  • Now

Alternative names

Department of Lymphoma and Hematology, Hunan Cancer Hospital

Active Ingredients

Drugs in Phase 2 Trials (2)

asparaginase (elspar) (1 trial)

chidamide (1 trial)

Indications

Experimental Indications (Clinical Trials, Phases 1-4)


 

Lymphoma (Phase 2)

Lymphoma, T-Cell (Phase 2)

Overview

  • Highest Phase: Phase 2
  • # of Trials: 1
  • # of Trial APIs: 2